Asset Details
Do you wish to reserve the book?
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
Do you wish to request the book?
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
2021
Overview
Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise
de novo
or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors
RB1, TP53,
and
PTEN
are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
